Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Eribulin · 1 trial · 2 indications
CBR defined as Partial Response (PR), Complete Response (CR) or Stable Disease (SD) by RECIST v1.1 in the combination therapy arm.
| Arm | Type | Description |
|---|---|---|
| Arm 1 - Single agent eribulin arm | EXPERIMENTAL | Eribulin until progression of disease (PD) as defined by RECIST v1.1, unacceptable toxicity or physician/patient discretion or choice to cease treatment. Patients who progress on the single agent eribulin arm may receive combination eribulin and pembrolizumab. |
| Arm 2 - Combination eribulin and pembrolizumab arm | EXPERIMENTAL | Eribulin for a maximum of 6 cycles. Pembrolizumab until PD or a maximum of 35 cycles (including the 6 cycles where it is administered in combination with eribulin) or until unacceptable toxicity or physician/patient discretion or choice to cease treatment. |
| Name | Type | Description |
|---|---|---|
| Eribulin Mesylate | DRUG | Eribulin mesilate is a first-in-class halichondrin B-based, microtubule dynamics inhibitor7. It inhibits the growth phase of microtubules without affecting the shortening phase and sequesters tubulin into non-productive aggregates. |
| Pembrolizumab | DRUG | Pembrolizumab is a potent humanized immunoglobulin G4 (IgG4) monoclonal antibody (mAb) with high specificity of binding to the programmed cell death 1 (PD 1) receptor, thus inhibiting its interaction with programmed cell death ligand 1 (PD-L1) and programmed cell death ligand 2 (PD-L2). |
Inclusion Criteria: 1. Provision of written informed consent prior to any study specific procedures and the ability to comply with the protocol for the duration of the study, including undergoing treatment and scheduled visits and examinations. 2. Patients \> 18 years old who have a histologically ...
Eribulin is a small molecule being studied for the treatment of ovarian carcinosarcoma. It is currently in Phase 2 clinical development and is investigational, meaning it has not been approved for this indication. The drug is being evaluated in combination with pembrolizumab in a clinical trial.
Eribulin is a small molecule that targets microtubules, inhibiting their polymerization and disrupting mitotic spindle formation, which leads to cell cycle arrest and apoptosis in cancer cells. This mechanism is being explored in the context of ovarian carcinosarcoma, a rare and aggressive gynecologic malignancy.
Eribulin is being developed by Pulmonx Corporation, a company traded on the NASDAQ under the ticker symbol LUNG. The company is conducting clinical research to evaluate the drug's safety and efficacy in patients with ovarian carcinosarcoma.
Eribulin is in Phase 2 clinical development for ovarian carcinosarcoma. It is an investigational drug and has not received FDA approval for this indication. The Phase 2 trial has been completed, and the results will inform further development decisions.
Eribulin is being studied in a Phase 2 clinical trial with the identifier NCT05619913, titled "EPOCH: Eribulin and Pembrolizumab in Ovarian/Uterine Carcinosarcoma." The trial enrolled 13 participants and was conducted in Australia, Canada, and the United Kingdom. It has been completed.
Eribulin is the active ingredient in the brand-name drug Halaven, which is approved for other indications such as metastatic breast cancer and liposarcoma. However, in the context of this clinical trial, it is being investigated for ovarian carcinosarcoma, an indication for which it is not yet approved.